Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion type Assertion NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_head.
- NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion description "[The expression profiles of the candidate genes were associated with 8-week disease control in patients with wild-type EGFR who had unresectable non-small cell lung cancer treated with erlotinib, but not in patients treated with sorafenib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_provenance.
- NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion evidence source_evidence_literature NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_provenance.
- NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion SIO_000772 25486910 NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_provenance.
- NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion wasDerivedFrom befree-2016 NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_provenance.
- NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_assertion wasGeneratedBy ECO_0000203 NP1246110.RA1tQ2tz32Q_bylnkIiLIgEMlwWinG-w1wxCB4aXfWUYM130_provenance.